Please log in
to access more information

loading...

User name and Password not recognised

Home Page > News > November 8TH, 2018

November 8TH, 2018

Biom’up announces completion of the 2018 scale-up of its manufacturing facility to meet commercial demand for HEMOBLASTTM Bellows

2018 scale-up of Biom’up’s manufacturing facility near Lyon (France) completed, allowing for a larger throughput and increased shipments of devices to the US and EU markets

Six key manufacturing processes upgraded, thoroughly reviewed and approved by the FDA and EMA; a strong validation of the Company capability to efficiently execute a comprehensive and demanding regulatory plan

Biom’up reaches a new important milestone in its growth strategy and continues to execute in line with commitments made at IPO

Saint-Priest (France), November 08, 2018, 8:00 am (Paris time) – Biom’up (the “Company”), a specialist in surgical hemostasis, announces today the completion of the 2018 scale-up of its manufacturing facility to meet commercial demand for HEMOBLASTTM Bellows, in the US and selected national markets in the EU. 

Download the full press release below: 

» 2018 0611 PR Biom'up US EU Launch EN.pdf